Search Results
Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246
High-risk MDS: pevonedistat and azacitidine vs azacitidine alone
Pevonedistat with azacitidine for high-risk MDS
APR-246 in TP53 mutated MDS and AML
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MD...
Sabatolimab plus HMAs in patients with HR-MDS and AML
The Therapeutic Revolution in management of Higher risk MDS: A focus on immunotherapy
Targeted Therapies (enasidenib, ivosidenib, APR-246)
Safety and efficacy of sabatolimab plus azacitidine or decitabine in patients with HR-MDS and AML
MDS: an update on pevonedistat plus azacitidine
Is azacitidine + APR-246 safe and effective in TP53 mutated MDS and AML?
Key clinical trials in high-risk and low-risk MDS
